The Oklahoma-based startup Linear Health Sciences is developing cutting-edge technology to prevent unwanted disconnection of IV’s. Their product, Orchid Valve, attaches to a standard IV luer lock, and if accidentally dislodged, the tubing will breakaway harmlessly, leaving the catheter in place. A new valve is then placed and the IV can be restarted without another catheter placement procedure, saving the patient from the discomfort of repeated IV attempts and the hospital time and money.
Linear Health Sciences has developed a simple, yet innovative technology that change how accidental IV removals are dealt with. The Orchid Valve is specifically designed with both the patient and the administrator in mind, minimizing the risk of complications and infections. IV therapy is the fastest way of delivering fluids and medications to the human body, and approximately 40% of all medications administered are given intravenously. The startup and their promising technology could increase success of treatment and ultimately improve patient outcomes, potentially saving lives.
In addition, replacing dislodged IVs is expensive, costing billions of dollars each year. The innovative solution can save up to 78% of incurred costs with unwanted IV removal, while minimizing time and resources. And the proprietary technology could potentially be applied to a wide variety of medical tubing, highlighting both the technology and the startup’s huge potential.
Linear Health Sciences was earlier in 2016 selected as a finalist in the Journal Record’s Innovator of the Year Award in Oklahoma, and was a semifinalist in the MedTech Innovator Competition before showcasing at AdvaMed 2016. In September 2016, the startup announced they had closed a $1.25 million seed round. The round was led by i2E and included $515,000 invested by Oklahoma Seed Capital Fund, $250,000 from the Oklahoma Angel Fund, $105,000 from SeedStep Angels and a total of $380,000 from other angel investors. The funding was used to develop manufacture grade tooling and molds for their Orchid Valve IV connection, and to finance the FDA approval process.